Protagonist Therapeutics (Australia)
Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2021
Protagonist Therapeutics appoints Scott Plevy to lead gastroenterology
Protagonist Therapeutics announced the appointment of Scott Plevy, M.D., as Executive Vice President and Therapeutic Head, Gastroenterology. He will oversee clinical operations and development of the company's gastrointestinal disease programs.
2021
Protagonist Therapeutics prices $115 million public offering
Protagonist Therapeutics announced the pricing of an underwritten public offering of 3,046,358 common shares at $37.75 per share, with gross proceeds expected to be approximately $115 million before expenses. The offering was expected to close on or about June 18, subject to customary conditions.